Section Editors

Inga Peters - Urologist and Senior Lecturer in the Department of Urology and Urologic Oncology at Hannover Medical School, Germany.

Inga Peters

Urologist and Senior Lecturer in the Department of Urology and Urologic Oncology at Hannover Medical School, Germany.

Dr Peters' research interests are the investigation of epigenetic biomarkers in renal cell carcinoma and prostate cancer as well as the development and improvement of imaging diagnostic tools (MRI-fusion, computer assisted TRUS) for the detection of prostate cancer.

Brad R Hirsch - Oncologist, Texas Oncology, Texas; Duke University School of Medicine

Brad R Hirsch

Oncologist, Texas Oncology, Texas; Duke University School of Medicine

Bertrand Tombal - Professor and Chairman, Service d’Urologie, Cliniques universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium.

Bertrand Tombal

Professor and Chairman, Service d’Urologie, Cliniques universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium.

Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine.

He is President of the Board of European Organization for Research and Treatment in Cancer (EORTC), the leading European academic research organization in the field of cancer.

He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA.

Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored many published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003.

Axel S Merseburger - Professor and Chairman of the Department of Urology in Lübeck, Germany

Axel S Merseburger

Professor and Chairman of the Department of Urology in Lübeck, Germany

Axel S Merseburger is the chairman of the Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Germany. Prof. Merseburger obtained his medical degree from Hannover Medical School in 2002 after a one-year academic research programme in Washington DC, USA, where he completed his MD thesis. In 2008, he accepted a staff position in Hannover and was promoted to associate professor in 2009; he obtained full professorship in 2012.

Prof. Merseburger is board certified in urology and is a member of numerous national and international urological and oncological associations. In addition to serving as a reviewer and member of the editorial board of many journals, Prof. Merseburger is the associate editor of the World Journal of Urology and Editor in Chief of the ‘Advanced Prostate Cancer Resource Centre’. Furthermore, he is a member of the European Association of Urology (EAU) Guideline Groups on renal cell cancer. He serves as national and international principal investigator in several phase II/III clinical trials. Prof. Merseburger has won multiple awards, stipends and prizes for his molecular and clinical research and has authored more the 200 peer review publications.

Special Feature

ESMO 2016 Immunotherapy for GU cancers: latest advances and future approaches The rapidly evolving field of immunotherapy in the treatment of genitourinary (GU) cancers was covered in a satellite symposium, sponsored by F. Hoffmann-La Roche, and held at the European Society for Medical Oncology (...

Latest Articles

Latest Videos

Video List based on Category on Node Page

Latest Videos

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for...
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What...
Editorial board member Ulka Vaishampayan from the Karmanos Cancer Center, Wayne State University, Detroit, MI, US, talks to us about the place of personalized therapy in patients with advance renal cancer and the potential role of X4P-001 in treatment paradigms in the near future. 1. What are...

Genitourinary Cancers INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Enzalutamide Treatment in Men with Nonmetastatic Prostate Cancer: Results of the PROSPER Study Katrina Mountfort
Medical Writer, Touch Medical Media, UK
Meeting Proceedings
Eisai and Merck Announce Latest Data on Lenvatinib and Pembrolizumab for Multiple Cancer Types at ASCO 2018 Katrina Mountfort
Medical Writer, Touch Medical Media, UK
Meeting Preview
EANM FOCUS 1: The First Focus Meeting of the European Association of Nuclear Medicine Katrina Mountfort, Medical Writer, Touch Medical Media, Goring-on-Thames, UK
Insight
ASCO 2017 Insight – High Dose Interleukin 2 Katrina Mountfort, Touch Medical Media, Reading, UK